Movement disorders clinical practice · 2023
Memantine Use and Cognitive Decline in Huntington's Disease: An Enroll-HD Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogilvie Amy C, Schultz Jordan L
Аннотация
BACKGROUND: Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist that is used to treat moderate to severe Alzheimer's Dementia (AD) and has been speculated to provide clinical benefits in Huntington's disease (HD).
OBJECTIVE: To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.
METHODS: Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.
RESULTS: In the primary analysis there were no significant differences in the trajectories between memantine users and non-users on any primary outcomes of interest.
CONCLUSIONS: Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.
OBJECTIVE: To assess the effectiveness of memantine on the trajectory of cognitive decline in individuals with manifest HD.
METHODS: Using participants from the Enroll-HD study, the primary analysis compared trajectories in cognition over a 5-year period using linear mixed effect models of prevalent and incident memantine users who were propensity-score-matched with non-users on measures of disease progression and demographics.
RESULTS: In the primary analysis there were no significant differences in the trajectories between memantine users and non-users on any primary outcomes of interest.
CONCLUSIONS: Memantine use was not associated with any clinical benefit for individuals with manifest HD. Further studies are warranted to assess the impact of memantine on clinical outcomes in HD.